Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Benzinga

By Meg Flippin, Benzinga Citius Pharmaceuticals Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company, is progressing with its focus on unlocking value for investors by announcing that shareholders of TenX Keane Acquisition (NASDAQ: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination between TenX Keane and Citius Pharma’s oncology subsidiary. The newly combined public company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology, Inc. In October, Citius announced it was spinning out its wholly-owned oncology unit to form Citius Oncology, a standalone publicly traded entity. Under the terms of the deal, Citius Pharma is getting 65.6 million shares of common stock of Citius Oncology, which would represent approximately 90% of the newly public company. As part of the transaction, Citius Pharma will contribute $10 million in cash to Citius Oncology. An additional 12.75 million existing options will be assumed by Citius Oncology. At closing, any cash remaining in TenX’s trust account along with the cash provided by Citius Pharma will be contributed to Citius Oncology for working capital and general corporate purposes of Citius Oncology following the transaction. Unlocking Significant Value Citius previously stated that the SPAC deal is expected to unlock significant value for Citius shareholders by separating the oncology business, potentially leading to increased access to capital markets and further development of new applications and additional intellectual property. It also underscores Citius’ strategy to purchase assets, develop them and bring them to market and then unlock shareholder value. First Out Of The Gate: LYMPHIR Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. The first to go to market will be LYMPHIR, a recombinant fusion protein designed to treat T-cell lymphomas. Citius said the deal is expected to provide Citius Oncology with improved access to the public equity markets and thereby facilitate the commercialization of LYMPHIR and position the company to explore additional value-creating opportunities more fully. The drug agent LYMPHIR combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. In 2011 and 2013, the FDA granted orphan drug designation to LYMPHIR for the treatment of peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL). In 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain other parts of Asia. In March this year, the FDA accepted Citius’s Biologics License Application (BLA) for LYMPHIR with a decision expected on August 13, 2024, the FDA's assigned Prescription Drug User Fee Act (PDUFA) action date. If approved, Citius is preparing for LYMPHIR commercialization later this year. “The reason we are doing this is acquire a Nasdaq listing by having the SPAC acquire the assets and at the same time it enables us to do something to prevent dilution for shareholders,” said Leonard Mazur, CEO of Citius in a recent interview with Benzinga. The CEO counts himself as one of the shareholders. He has invested $22.5 million of his own money in the business. “During the first year on the market we will be profitable. All that benefits Citius shareholders,” he said. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 06, 2024 10:45 AM Eastern Daylight Time

Image

HPS/PayMedix Acquires TempoPay to Further Expand and Simplify Healthcare Payments for All

HPS|PayMedix

HPS/PayMedix today announced the acquisition of TempoPay, an innovative payments solution created at Redesign Health that helps employees access medical, dental, pharmacy, and other expenses not paid by their insurance. Together, HPS/PayMedix and TempoPay now offer a comprehensive healthcare financing and payments solution, addressing the issues of health equity, affordability, and the need to simplify the healthcare payments experience. According to the PayMedix Healthcare Payments and Financial Disparities Study, one-third of Americans say out-of-pocket costs (33%) and deductibles (31%) are unaffordable. This figure increases to four in ten for those with a credit score of 669 or less. Further, more than half (52%) of insured Americans said that paying for medical bills has been stressful, with nearly all of them (92%) claiming the stress has affected their physical and mental health. “Healthcare costs are increasingly becoming a disproportionate share of the American household wallet, and we need better solutions to manage the stress this puts on family budgets,” said Tom Policelli, CEO of HPS/PayMedix. “The acquisition of TempoPay underscores our mission to simplify healthcare and create greater health equity by removing the financial barriers that stand in the way of employees getting access to the care they need when they need it; not just when they feel that they can afford it.” TempoPay offers all an employer’s employees’ interest-free financing for health and wellbeing care that overlays their current plans. Once activated by the employee, TempoPay VISA® cards can be used to pay for everything from medical care and prescriptions to vision and dental bills; even vet bills for their pet and other approved health and wellness-related costs not covered by their plans. The employer sets the dollar amount and charge types that will be processed, and employees can repay their bills over time interest-free via payroll or bank account. “TempoPay is the lifeline employees need today so they can access care and maintain their health without fearing high interest bills or avoiding needed care,” Erika Davison-Aviles, CEO and Co-founder of TempoPay said. “We are excited to become a part of HPS/PayMedix’s innovative healthcare payment solution and further our mission to alleviate consumers’ financial pressure. For employers we help maximize the value of their benefits plans, pre-tax accounts, and other well-being programs.” With TempoPay and PayMedix combined, all employees can access interest-free financing for all their healthcare needs. While TempoPay offers immediate financing of everyday healthcare expenses, PayMedix provides complete, uncapped financing for all in-network allowed charges that any employee may owe to providers. All employees are automatically enrolled and PayMedix then pays all participating providers in full. The employees each get a simplified consolidated statement (a SuperEOB) each month and can arrange to pay it on terms that fit their budgets. Participating providers, in turn, are simply paid the full employee balance due automatically and therefore have no bill to collect. Because PayMedix and TempoPay are ‘credit-blind’, all employees, regardless their credit histories, can make their healthcare expenses more manageable. “It’s a fact that 1 in 4 PayMedix members would be unable to get financing for their healthcare based on their credit scores. With TempoPay, we can reach even more members to help them get and stay healthy,” said Brian Marsella, President of HPS/PayMedix. “The powerful combination of PayMedix and TempoPay provides employers with a valuable solution to support their workforce. We have proven that improving access to care drives better outcomes – particularly for lower-income employees. This in turn saves employers money.” About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With theTempoPay Visa ® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. About HPS Health Payment Systems (HPS) is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 100+ hospital facilities and 29,200+ individual providers. Contact Details Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://paymedix.com

August 06, 2024 08:00 AM Eastern Daylight Time

NAVEX to Demystify IT Risk Communication at ISACA GRC Conference

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, will deliver a key session at the upcoming ISACA Governance, Risk, and Control (GRC) Conference in Austin, Texas, August 12-14, 2024. The session, " Getting Our Wires Crossed: How to Speak IT Risk as a Compliance Professional," will be presented by Kyle Martin, Vice President of GRC Solutions at NAVEX, and Robert Clark, Chief Audit and Compliance Officer at Howard University. In an era where cybersecurity threats and regulatory pressures are at an all-time high, the ability to effectively communicate IT risks across organizational silos has become a critical skill for compliance professionals. Attendees can join the session, CS 7–4, on August 13th at 11:00 to gain valuable insights into: Understanding and translating risk and compliance terminology. Evaluating program maturity levels and their organizational implications. Assessing risks and controls across all business facets, including third-party risk management. Crafting compelling IT risk reports for executive teams and board directors. "In today's interconnected business environment, the ability to translate IT risk insights into compelling narratives for CEOs is no longer optional—it's essential," said Kyle Martin. "As a result, this session aims to empower compliance professionals with the tools they need to navigate this critical intersection confidently." The ISACA GRC Conference, now in its 11th year, brings together leading minds in governance, risk management, and control to provide world-class content and practical guidance. NAVEX's participation underscores its commitment to advancing the field of integrated risk and compliance management. For more information about NAVEX's participation in the ISACA GRC Conference 2024 or to schedule an interview with the speakers, please contact Senior Public Relations Manager, Scott Levesque at scott.levesque@navex.com. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

August 06, 2024 08:00 AM Eastern Daylight Time

AmeriLife Welcomes Elite Insurance Group to Its Rapidly Expanding Health Distribution Network

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that it has partnered with Elite Insurance Group, an independent, Reidsville, Georgia-based insurance brokerage that specializes in the Medicare, health insurance, and life insurance markets. Per the agreement, terms of the deal were not disclosed. “We are so happy to become part of the AmeriLife family,” said David Wilson, owner and Chief Executive Officer of Elite Insurance Group. “This partnership will allow us to take our business to the next level and ensure the continued success of our company.” “This partnership gives us and our employees the opportunity to provide outstanding resources and benefits that our clients deserve,” added Hunter Davis, Chief Operating Officer of Elite Insurance Group. “We look forward to expanding the excellence of the Elite Insurance Group brand with our new partners.” Elite Insurance Group, which is licensed in 28 states and has satellite offices in Alabama, Virginia, and Kentucky, has been serving the senior market since 2005, by simplifying the health and life insurance buying process for clients – all with a personal touch. As a full-service brokerage founded on the values of honesty, integrity, and trust, the company offers deep and diverse plan options from some of the industry’s top carriers to ensure its clients find the best benefits and savings for themselves and their families. As Elite Insurance Group joins AmeriLife’s growing Health Distribution organization, it will enjoy access to a number of best-in-class platforms, tools, and resources that will help accelerate its already impressive growth and serve more beneficiaries. “I’m thrilled to welcome David, Hunter, and their ‘Elite’ team to AmeriLife,” said Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. “As we continue to navigate disruption and change throughout our industry, it’s important that we bring onboard strong, resilient partners who are built for clients’ needs today and tomorrow, and Elite Insurance Group is exactly that kind of partner. We can’t wait to get to work together.” ### About Elite Insurance Group Since 2005, Elite Insurance Group has been specializing in the senior market. As an independent insurance company, we strive to uphold professional values such as honesty, integrity, and trust. By following these guiding principles, we have become just what our name states: elite. Our mission at Elite Insurance Group is to support and provide our agents with the resources they need to serve the senior market with the appropriate selections of health and life insurance products they and their clients need. To learn more, visit Elite-InsGroup.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as a leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

August 01, 2024 09:00 AM Eastern Daylight Time

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Benzinga

By Anthony Termini, Benzinga According to Cancer Research UK, "Cancer survival has doubled in the last 40 years, but progress hasn’t been equal across all types of the disease." Their research shows that survival rates of some forms of brain tumors and pancreatic cancers have barely improved in that time. One company has made it its mission to change that. Theriva TM Biologics Has A Novel Approach To Address Difficult-To-Treat Cancers Theriva Biologics (AMEX: TOVX) is headquartered in Rockville, Maryland, and its clinical research efforts span the Atlantic. Theriva is a leader in the development of oncolytic virus therapies – treating cancer with viruses that target tumors. The company recently announced positive results from one of its several ongoing clinical trials. Theriva’s oncolytic viruses are designed to address a wide range of difficult-to-treat tumor types. “Solid tumors are complex organ-like structures consisting of cancer cells, vasculature, and tumor matrix,” said Steven A. Shallcross, CEO of Theriva. He added that “this dense extracellular matrix, also known as stroma, hampers the intratumoral accessibility of chemotherapy, making them hard to treat.” And these are the challenges that Theriva seeks to address in a number of clinical trials. How Theriva Focuses Specific Oncolytic Viruses To Treat Various Cancers Theriva says its viruses have the potential to treat a broad range of difficult-to-treat tumor types. Their leading candidate, VCN-01, is a stroma-degrading oncolytic virus. It is intended to break down the tumor’s protective barrier and improve tumor access by co-administered cancer therapies and the patient’s immune system. It may be combined with other types of cancer therapies to treat a number of tumor types. Theriva has reported encouraging results from clinical trials in pancreatic cancer (PDAC), retinoblastoma and head and neck squamous cell carcinomas (HNSCC). Ongoing clinical trials conducted in collaboration with the School of Medicine at the University of Leeds in England and the University of Pennsylvania's Perelman School of Medicine are evaluating VCN-01 in other difficult to treat cancers.. Theriva’s additional next generation oncolytic viruses such as VCN-11, which incorporates the novel Albumin Shield technology, are in preclinical development in collaboration with researchers from at the Institut d’Investigació Biomèdica de Bellvitge ( I DIBELL) and the Catalan Institute of Oncology ( ICO ). These studies are being conducted to determine safe dosage protocols and assess potential toxicity issues. The data from the tests will help inform clinical trial plans and other important aspects of product development programs. In conjunction with Washington University in St. Louis, Theriva is also investigating an approach to prevent acute graft-versus-host disease (aGVHD), a common and serious immune complication in allogeneic hematopoietic cell transplantation (allo-HCT). Allo-HCT, commonly known as bone marrow transplantation, is used to treat hematologic cancers, which begin in blood-forming tissue or immune system cells. Theriva’s oral β-lactamase (SYN-004), is an antibiotic-degrading enzyme being evaluated as a way to prevent aGVHD and other serious side effects caused by extensive use of antibiotics in these high-risk patients.. Addressing Difficult-To-Treat Cancers Represents Significant Commercial Opportunity The various types of solid tumors that Theriva’s oncolytic virus therapies treat represent a global commercial opportunity that could be as large as $532 billion by 2032, according to Precedence Research. Other analysts estimate the global market will be over $885 billion by 2033. Grand View Research estimates the global retinoblastoma treatment market will reach more than $3.3 billion by 2030. In its estimate of the growing market for treating the disease, Grand View attributes growing advancements in medical technology and the rising incidence of retinoblastoma. Theriva Has High Hopes For Its Therapies In a poster presented at the 2024 meeting of the American Society of Clinical Oncology, the principal investigator and country coordinator of Theriva’s main clinical site in Spain, Dr. Rocio Garcia-Carbonero detailed the clinical trial design for the VIRAGE Phase 2b clinical trial of VCN-01 when administered to PDAC patients in combination with standard of care chemotherapy. In a recent interview, Garcia-Carbonero noted that metastatic PDAC has a high fatality rate despite recent treatment advancements. While the field has seen minimal improvement in standard care for decades, she said that she has “high hopes for VCN-01 due to its unique mechanism of action, which differs from traditional chemotherapy. VCN-01 aims to induce a robust immune response against the cancer.” More information about Theriva’s oncolytic virus therapies is available on the company’s website. Featured photo by Prawny from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 01, 2024 08:35 AM Eastern Daylight Time

Image

News Release

Zynex Inc. CEO Thomas Sandgaard Discusses Significant Company Growth and Future Innovations

Zynex Medical

Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the company's financial and operational results for the second quarter ending June 30, 2024, in an interview with Proactive. The company achieved a remarkable 20% year-over-year increase in orders, marking the ninth consecutive quarter of record-breaking order numbers. Zynex reported an 11% year-over-year increase in second-quarter revenue, totaling $49.9 million, and a 20% increase in year-to-date cash flow from operations, reaching $3.2 million. Sandgaard emphasized the company's ongoing efforts to secure FDA approvals for next-generation devices and expand its product line in pain management. The pain management division saw a significant 20% improvement in orders compared to the previous year, highlighting strong market demand. Looking ahead, Zynex has provided guidance for the third quarter, with revenue expected to reach at least $50.0 million. Zynex's pain management devices are prescribed for various conditions, from post-surgical recovery to general pain management, by a diverse group of medical professionals, including surgeons, general practitioners, and chiropractors..In terms of innovation, Zynex is developing new monitoring devices, including a pulse oximeter based on laser technology for more accurate blood measurements, which could also detect sepsis. This product, along with others in development, positions Zynex to potentially capture significant market share. The company aims to diversify its product portfolio. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 31, 2024 09:42 AM Eastern Daylight Time

Video

Syra Health Wins Contract Valued At Nearly $6M To Train Indiana Health Workers

Syra Health

By Kyle Anthony, Benzinga Syra Health Corp. (NASDAQ: SYRA), has been awarded a $5.8 million contract to train professionals who deliver healthcare to Indiana residents at home or in a community-based setting under the purview of the Indiana Family and Social Services Administration (FSSA). Headquartered in Carmel, Indiana, Syra Health was founded in 2020 and is focused on improving healthcare through innovative services and technology solutions. At its core, the company is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health. Syra Health's offerings are centered on prevention, improved access, and affordable care. In securing this new contract, Syra Health says it will deliver curriculum development, competency assessments, a sophisticated learning management system (LMS), a comprehensive training registry, and a dynamic quality improvement plan, all to fulfill FSSA's vision of "ensuring all home and community support professionals serving any population under a home and community-based settings waiver have the same competencies and training." In speaking about being selected for this new contract, Dr. Deepika Vuppalanchi, CEO of Syra Health, stated, “We are proud to have been selected to implement statewide home and community support professionals training as part of this important program administered by FSSA. In recent months, we have seen a surge in demand for our off-the-shelf training services, and we look forward to providing additional health training services across the country.” Syra Health’s curriculum reflects important gold-standard learning models and over 200 years of experience. It has module-specific learning objectives and interactive activities across the foundational, fundamentals, medication administration, and micro-credentials curricula. These areas, aligned with state-defined core competencies, integrate health equity and cultural competency principles aimed at supporting home and community support professionals of all backgrounds. Syra Health’s training registry will track the utilization of the training materials and will be integrated into the LMS. As such, it will be able to provide a snapshot of workforce capacity and competency at any given moment in time. Effective monitoring and reporting will also be a critical aspect of this project. Syra Health says it will be providing regular comprehensive reports to the FSSA and modifying the process to meet any evolving monitoring or reporting needs. Featured photo by Ani Kolleshi on Unsplash. Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health’s products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com. Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy and the Company’s expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Drury +1 463-345-8950 Christined@syrahealth.com Company Website https://www.syrahealth.com/

July 31, 2024 08:55 AM Eastern Daylight Time

Image

News Release

Acarix announces shares are now being traded on the OTCQB under the ticker ACIXF

Acarix AB

Acarix CEO Aamir Mahmood joined Steve Darling from Proactive to share news the company has begun trading on the OTCQB Market in the United States, under the ticker symbol ACIXF. This listing complements its existing presence on the Nasdaq First North Growth Market in Stockholm. Mahmood expressed that with the US being Acarix's most important commercial market, this development allows for a broader investor base to participate in the company’s growth journey. Acarix specializes in medical devices aimed at rapid assessment of coronary artery disease (CAD) at the point of care. The company's flagship product, the CADScor System, is CE-approved and FDA DeNovo-cleared, offering a non-invasive solution to help healthcare providers rule out CAD in patients experiencing chest pain, potentially reducing the need for costly and invasive diagnostic procedures. The company recently announced a significant reorder of single-use patches for the CADScor System by a primary care clinic in the New Orleans, Louisiana metropolitan area. These patches are integral to the system's operation in evaluating patients suspected of having coronary artery disease. Additionally, Acarix has received a multi-order for the CADScor System from Saving Grace Concierge, which will use it as a diagnostic aid for symptomatic patients in the Oklahoma City and Tulsa metro areas. Looking ahead, Mahmood outlined the company's focus on top-line growth, reimbursement efforts with CMS and private payers, and initiating clinical trials. He emphasized the device's potential to save significant healthcare costs and drive commercial success in the US market. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 30, 2024 10:58 AM Eastern Daylight Time

Video

LeadStar and LeadingResponse Announce Strategic Partnership to Enhance Lead Generation with In-Person Seminar Programming

AmeriLife

LeadStar, the proprietary, private leads platform created with and exclusively for AmeriLife -affiliated agents, announced today that it has partnered with LeadingResponse to launch LeadStar Seminars Powered by LeadingResponse to strengthen its spectrum of lead options and provide AmeriLife agents with a comprehensive seminars services platform to offer face-to-face educational opportunities for health and life insurance and financial services customers. LeadStar Seminars Powered by LeadingResponse is the newest addition to the LeadStar platform, which now provides a comprehensive set of lead delivery options. LeadingResponse’s dynamic seminar programming will provide agents with a seamless experience from lead acquisition to conversion, with services that include real-time lead delivery, comprehensive campaign management, and expertly crafted seminar content designed to engage and convert. “This partnership is a game-changer for AmeriLife’s Health and Wealth professionals looking to drive growth and enhance live engagement with their target audiences,” said Chief Lead Officer for AmeriLife William DeCourcy. "We recognize that there is no ‘one size fits all’ approach to delivering compliant, high-performance leads to AmeriLife agents. Partnering with LeadingResponse expands the lead options available to AmeriLife agents, allowing health and wealth product sales professionals to scale efficiently and effectively in multiple channels – including the key channel of face-to-face educational seminars.” LeadingResponse, with decades of experience in targeted seminar marketing, brings unparalleled expertise in engaging affluent consumers through in-person seminars, webinars, and multichannel marketing approaches. Their proven conversion strategies in educational workshops and seminar solutions have filled countless events with qualified consumers, perfectly complementing LeadStar's capabilities in lead generation. “We are excited about our partnership with AmeriLife and LeadStar,” said Matthew Kearney, Chief Executive Officer for LeadingResponse. “We look for partners that share in our mission to connect health and wealth experts to consumers exactly when help is needed, and AmeriLife and LeadStar are a perfect fit. By leveraging our expertise, concierge service, and advanced technology, AmeriLife sales professionals can grow their businesses through our highly effective solution suite.” The LeadingResponse platform includes targeted audience reach specifically designed to target affluent consumers aged 50 and above; a robust client portal, Hub, which allows for 24/7 review of ongoing campaigns while integrating with your CRM and marketing automation workflows; and high conversion rates through seminar attendance, with attendee rates over twice the industry average. “LeadStar Seminars Powered by LeadingResponse represent a significant step forward in our ongoing efforts to provide AmeriLife’s distribution partners with the tools and strategies they need to succeed in a competitive marketplace,” added DeCourcy. “We are confident that LeadStar Seminars Powered by LeadingResponse can drive client growth with data-driven insights and marketing solutions that optimize LeadStar’s lead generation suite of services to achieve strong outcomes.” AmeriLife-affiliated licensed health agents and financial professionals interested in leveraging LeadStar Seminars Powered by LeadingResponse are encouraged to inquire with their marketers or uplines about access to these integrated services, promising a boost in both the quantity and quality of leads and conversions. For more information about the partnership and to request access, please visit the LeadStar Seminars Powered by LeadingResponse page on the LeadStar website. ### About LeadStar LeadStar is an industry-leading enterprise leads program that delivers the compliant, reliable, and performative leads that today’s health and life insurance agents need to grow their books of business and maximize their success. Powered by AmeriLife and exclusively for the company’s affiliated agents, LeadStar’s suite of solutions includes LeadStar Marketplace, LeadStar Connect, LeadStar Direct, and LeadStar Seminars Powered by LeadingResponse. For more information, contact an AmeriLife-affiliated marketing company or visit LeadStarHub.com. About LeadingResponse Founded in 1996 with headquarters in Tampa, LeadingResponse is a trusted and proven leader in customer acquisition for health and wealth organizations across the United States. LeadingResponse’s solution suite enables clients to connect with consumers in the medium they want to engage and at the point in the consumer journey clients wish to target. Whether consumers need Preneed, legal defense, financial advice, a senior living community, Estate Planning, or a Medicare procedure, LeadingResponse connects our client experts to provide the needed consultation. With our teams of marketers, designers, and developers, LeadingResponse is the easiest way for organizations to grow their business and increase revenue. For more information, visit the LeadingResponse website. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details Jeff Maldonado media@amerilife.com LeadingResponse Pamela Girardin pamela.girardin@leadingresponse.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

July 30, 2024 09:00 AM Eastern Daylight Time

1 2 3 4 5 ... 266